Antineoplastic Agents ; pharmacology ; Autophagy ; drug effects ; Disulfides ; pharmacology ; Gene Expression Regulation, Neoplastic ; Glycogen Synthase Kinase 3 ; genetics ; metabolism ; HCT116 Cells ; Humans ; Piperazines ; pharmacology ; Proto-Oncogene Proteins ; genetics ; metabolism ; Proto-Oncogene Proteins p21(ras) ; Signal Transduction ; ras Proteins ; genetics ; metabolism

Objective To introduce a breast conserving surgery for reconstruction of breast shape and to demonstrate the postoperative effect.Methods Ten patients were treated with this method from Apr.2016 to Dec.2017,and the lateral thoracic wall arteriovenous vessels were used as vascular pedicle to transfer the distal compound tissue flap of the blood vessel to repair the breast defect remnant cavity which was formed after the breast conserving surgery,and a good shape was obtained.Results All the 10 cases were successfully completed.The intraoperative bleeding was 20 to 30 ml.The operative time was 2 to 3 hours.No blood transfusion was needed.The average hospital stay was 11.5 days,ranging from 10 to 15 days.No infection happened to the incision.All the 10 patients were followed up from 2 to 20 months,with 11 months as the average.No limb edema,asymmetry or local recurrence happened.Conclusion The operation method is effective,safe and economical for patients with large swelling but strong desire to conserve breast.

COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.